Gurudutt P. Varty
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Gurudutt P. Varty has a total of 41 co-authors. Here are the top co-authors by number of shared publications:
- Mahesh Goel
Department of Surgical Oncology Tata Memorial Hospital and Homi Bhabha National Institution Mumbai India
11 shared publications - Shraddha Patkar
Department of Surgical Oncology, Tata Memorial Hospital, Mumbai, India
11 shared publications - Kunal Nandy
Division of GI and HPB Surgery, Department of Surgical Oncology, Tata Memorial Hospital, Homi Bhabha National Institute, Mumbai, India
6 shared publications - Mufaddal Kazi
Department of Surgical Oncology, Tata Memorial Hospital, Mumbai, India
5 shared publications - Anant Ramaswamy
Department of Medical Oncology, Tata Memorial Centre, Homi Bhabha National Institute, Mumbai, Maharashtra, India
4 shared publications - Tanvi M. Shah
Department of Surgical Oncology Tata Memorial Hospital and Homi Bhabha National Institution Mumbai India
4 shared publications
Latest Publications
- 27 February 2026
- Published by Springer Nature in Indian Journal of Surgical Oncology
- Vol. 17 (4) , 734-743
Extranodal Follicular Dendritic Cell Sarcomas and their Oligorecurrences: Lessons Learnt at a Single Tertiary Cancer Referral Centre, India
Background Follicular dendritic cell sarcoma (FDCS) is a rare, aggressive malignant neoplasm usually arising in lymph nodes of the head and neck, but it can also occur at extranodal sites (ENFDCS). Due to its rarity, optimal management is not well defined, underscoring the need for further research. Methods We conducted a retrospective analysis of patients with histologically confirmed ENFDCS treated in the gastrointestinal oncology unit of a tertiary cancer center. Clinical features, treatments, and outcomes were reviewed. Results Fourteen patients (10 males, 4 females; median age 41 years) were included. Primary sites were colon (n = 6), retroperitoneum (n = 3), rectum (n = 2), mesentery (n = 1), liver (n = 1), and pelvis (n = 1). Four tumors (28.6%) were initially misdiagnosed. Final diagnosis was based on morphology and immunohistochemistry for CD21, CD23, and CD35; Epstein–Barr virus testing was not performed. Five patients underwent primary surgery at our center; two patients with metastatic disease at presentation received systemic therapy alone. Among the five primary surgeries, three were preceded by perioperative chemotherapy (n = 1), neoadjuvant chemotherapy (n = 1), or neoadjuvant radiotherapy (n = 1). Seven patients presented with residual or recurrent disease after prior surgery elsewhere; three underwent re-resection following appropriate systemic therapy, and four received only systemic therapy. At a median follow-up of 26 months (range 7–153), median overall survival was not reached, and median disease-free survival was 24 months. Four of five patients primarily operated at our center remained disease free; one recurred at 39 months, was successfully treated with re-resection and systemic therapy, and was alive at 153 months. Of the three patients re-resected at our center, one remained disease free at 17 months, one developed systemic recurrence and eventually received best supportive care at 11 months, and one was disease free until 94 months before being lost to follow-up. Overall, 10 patients were alive, two died of disease progression, and two were lost to follow-up. Conclusion ENFDCS is frequently misdiagnosed; surgery is the cornerstone of treatment, and multimodality therapy for recurrences can yield durable survival. Outcomes appear better when patients are managed at specialized oncologic centers, highlighting the importance of early recognition and timely referral. Graphical Abstract
- 27 February 2026
- Published by Springer Nature in Indian Journal of Surgical Oncology
- Vol. 17 (4) , 734-743
Extranodal Follicular Dendritic Cell Sarcomas and their Oligorecurrences: Lessons Learnt at a Single Tertiary Cancer Referral Centre, India
Background Follicular dendritic cell sarcoma (FDCS) is a rare, aggressive malignant neoplasm usually arising in lymph nodes of the head and neck, but it can also occur at extranodal sites (ENFDCS). Due to its rarity, optimal management is not well defined, underscoring the need for further research. Methods We conducted a retrospective analysis of patients with histologically confirmed ENFDCS treated in the gastrointestinal oncology unit of a tertiary cancer center. Clinical features, treatments, and outcomes were reviewed. Results Fourteen patients (10 males, 4 females; median age 41 years) were included. Primary sites were colon (n = 6), retroperitoneum (n = 3), rectum (n = 2), mesentery (n = 1), liver (n = 1), and pelvis (n = 1). Four tumors (28.6%) were initially misdiagnosed. Final diagnosis was based on morphology and immunohistochemistry for CD21, CD23, and CD35; Epstein–Barr virus testing was not performed. Five patients underwent primary surgery at our center; two patients with metastatic disease at presentation received systemic therapy alone. Among the five primary surgeries, three were preceded by perioperative chemotherapy (n = 1), neoadjuvant chemotherapy (n = 1), or neoadjuvant radiotherapy (n = 1). Seven patients presented with residual or recurrent disease after prior surgery elsewhere; three underwent re-resection following appropriate systemic therapy, and four received only systemic therapy. At a median follow-up of 26 months (range 7–153), median overall survival was not reached, and median disease-free survival was 24 months. Four of five patients primarily operated at our center remained disease free; one recurred at 39 months, was successfully treated with re-resection and systemic therapy, and was alive at 153 months. Of the three patients re-resected at our center, one remained disease free at 17 months, one developed systemic recurrence and eventually received best supportive care at 11 months, and one was disease free until 94 months before being lost to follow-up. Overall, 10 patients were alive, two died of disease progression, and two were lost to follow-up. Conclusion ENFDCS is frequently misdiagnosed; surgery is the cornerstone of treatment, and multimodality therapy for recurrences can yield durable survival. Outcomes appear better when patients are managed at specialized oncologic centers, highlighting the importance of early recognition and timely referral. Graphical Abstract
- 7 October 2025
- Published by Elsevier in European Journal of Surgical Oncology
- Vol. 51 (12) , 110492
Development of a novel predictive nomogram to prevent ‘futile surgery’ in gallbladder cancers: A single center analysis of 1196 resected gallbladder cancers
- 7 October 2025
- Published by Elsevier in European Journal of Surgical Oncology
- Vol. 51 (12) , 110492
Development of a novel predictive nomogram to prevent ‘futile surgery’ in gallbladder cancers: A single center analysis of 1196 resected gallbladder cancers
- 22 October 2024
- Published by Elsevier in Journal of Gastrointestinal Surgery
- Vol. 29 (1) , 101868
Optimal treatment strategies for borderline resectable liver metastases from colorectal cancer
- 22 October 2024
- Published by Elsevier in Journal of Gastrointestinal Surgery
- Vol. 29 (1) , 101868
Optimal treatment strategies for borderline resectable liver metastases from colorectal cancer
- 13 September 2024
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 31 (12) , 7911-7912
ASO Visual Abstract: Realizing Textbook Outcomes Following Liver Resection for Hepatic Neoplasms with Development and Validation of a Predictive Nomogram
- 13 September 2024
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 31 (12) , 7911-7912
ASO Visual Abstract: Realizing Textbook Outcomes Following Liver Resection for Hepatic Neoplasms with Development and Validation of a Predictive Nomogram
- Open Access
- 20 August 2024
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 31 (13) , 9225-9226
ASO Author Reflections: Transition to Robotic Radical Cholecystectomy: Building the Future on Strong Fundamentals
- 20 August 2024
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 31 (13) , 9225-9226
Open AccessASO Author Reflections: Transition to Robotic Radical Cholecystectomy: Building the Future on Strong Fundamentals
- Open Access
- 5 August 2024
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 31 (12) , 7870-7881
Realizing Textbook Outcomes Following Liver Resection for Hepatic Neoplasms with Development and Validation of a Predictive Nomogram
Background: ‘Textbook Outcome’ (TO) represents an effort to define a standardized, composite quality benchmark based on intraoperative and postoperative endpoints. This study aimed to assess the applicability of TO as an outcome measure following liver resection for hepatic neoplasms from a low- to middle-income economy and determine its impact on long-term survival. Based on identified perioperative predictors, we developed and validated a nomogram-based scoring and risk stratification system. Methods: We retrospectively analyzed patients undergoing curative resections for hepatic neoplasms between 2012 and 2023. Rates of TO were assessed over time and factors associated with achieving a TO were evaluated. Using stepwise regression, a prediction nomogram for achieving TO was established based on perioperative risk factors. Results: Of the 1018 consecutive patients who underwent liver resections, a TO was achieved in 64.9% (661/1018). The factor most responsible for not achieving TO was significant post-hepatectomy liver failure (22%). Realization of TO was independently associated with improved overall and disease-free survival. On logistic regression, American Society of Anesthesiologists score of 2 (p = 0.0002), perihilar cholangiocarcinoma (p = 0.011), major hepatectomy (p = 0.0006), blood loss >1500 mL (p = 0.007), and presence of lymphovascular emboli on pathology (p = 0.026) were associated with the non-realization of TO. These independent risk factors were integrated into a nomogram prediction model with the predictive efficiency for TO (area under the curve 75.21%, 95% confidence interval 70.69–79.72%). Conclusion: TO is a realizable outcome measure and should be adopted. We recommend the use of the nomogram proposed as a convenient tool for patient selection and prognosticating outcomes following hepatectomy.
- 5 August 2024
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 31 (12) , 7870-7881
Open AccessRealizing Textbook Outcomes Following Liver Resection for Hepatic Neoplasms with Development and Validation of a Predictive Nomogram
Background: ‘Textbook Outcome’ (TO) represents an effort to define a standardized, composite quality benchmark based on intraoperative and postoperative endpoints. This study aimed to assess the applicability of TO as an outcome measure following liver resection for hepatic neoplasms from a low- to middle-income economy and determine its impact on long-term survival. Based on identified perioperative predictors, we developed and validated a nomogram-based scoring and risk stratification system. Methods: We retrospectively analyzed patients undergoing curative resections for hepatic neoplasms between 2012 and 2023. Rates of TO were assessed over time and factors associated with achieving a TO were evaluated. Using stepwise regression, a prediction nomogram for achieving TO was established based on perioperative risk factors. Results: Of the 1018 consecutive patients who underwent liver resections, a TO was achieved in 64.9% (661/1018). The factor most responsible for not achieving TO was significant post-hepatectomy liver failure (22%). Realization of TO was independently associated with improved overall and disease-free survival. On logistic regression, American Society of Anesthesiologists score of 2 (p = 0.0002), perihilar cholangiocarcinoma (p = 0.011), major hepatectomy (p = 0.0006), blood loss >1500 mL (p = 0.007), and presence of lymphovascular emboli on pathology (p = 0.026) were associated with the non-realization of TO. These independent risk factors were integrated into a nomogram prediction model with the predictive efficiency for TO (area under the curve 75.21%, 95% confidence interval 70.69–79.72%). Conclusion: TO is a realizable outcome measure and should be adopted. We recommend the use of the nomogram proposed as a convenient tool for patient selection and prognosticating outcomes following hepatectomy.
- 18 April 2024
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 31 (8) , 5431-5432
En Bloc Inferior Vena Cava (IVC) Resection Without Reconstruction With Right Hepatectomy and Right Nephrectomy for a Large IVC Leiomyosarcoma
Radical resection remains the only potential cure in the management of inferior vena cava (IVC) leiomyosarcomas with multivisceral resections often needed
- 18 April 2024
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 31 (8) , 5431-5432
En Bloc Inferior Vena Cava (IVC) Resection Without Reconstruction With Right Hepatectomy and Right Nephrectomy for a Large IVC Leiomyosarcoma
Radical resection remains the only potential cure in the management of inferior vena cava (IVC) leiomyosarcomas with multivisceral resections often needed
- 4 April 2024
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 31 (6) , 1-2
ASO Author Reflections: Advancing the Frontiers of Robotic Pancreaticoduodenectomy: Where are We Headed?
- 4 April 2024
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 31 (6) , 1-2
ASO Author Reflections: Advancing the Frontiers of Robotic Pancreaticoduodenectomy: Where are We Headed?